What is YBRAIN?
YBRAIN is a pioneering entity in the development and commercialization of electronic drugs designed to alleviate depression. The company harnesses neuroscience-based technology to offer a comprehensive mental health care platform, facilitating at-home treatment solutions that prioritize safety and user convenience. Their flagship products, MINDD SCAN and MINDD STIM+, are engineered to enhance mental health care delivery and have demonstrated efficacy through clinical trials. Ybrain's strategic focus is on providing innovative mental health solutions to both healthcare providers and patients.
How much funding has YBRAIN raised?
YBRAIN has raised a total of $3.5M across 1 funding round:
Series A
$3.5M
Series A (2014): $3.5M with participation from Stonebridge Capital
Key Investors in YBRAIN
Stonebridge Capital
Stonebridge Capital is an investment firm focused on providing personalized financial and investment planning services. Their philosophy centers on understanding client goals to develop tailored strategies for wealth creation and asset protection.
What's next for YBRAIN?
With a substantial enterprise-level funding context, YBRAIN is poised for significant scaling and market expansion. The recent strategic investment signals strong investor confidence in their innovative approach to mental health treatment. This backing will likely fuel further research and development, enhance manufacturing capabilities for their electronic drug devices, and broaden their market reach. YBRAIN's trajectory suggests a move towards solidifying its position as a leader in the digital therapeutics space, potentially exploring new therapeutic applications and partnerships to further its mission of accessible mental health care.
See full YBRAIN company page
